Literature DB >> 32642171

Is needle biopsy a risk factor of pleural recurrence after surgery for non-small cell lung cancer?

Takahide Toyoda1, Hidemi Suzuki1, Atsushi Hata1, Takayoshi Yamamoto1, Junichi Morimoto1, Yuichi Sakairi1, Hironobu Wada1, Takahiro Nakajima1, Ichiro Yoshino1.   

Abstract

BACKGROUND: Tumor seeding, whereby malignant cells are deposited along the needle tract, is considered to be a potential hazard of needle biopsies. The aim of this study is to elucidate the relationship between needle biopsies for lung tumor, such as a preoperative computed tomography-guided needle biopsy (PCTGNB) or an intraoperative fine-needle aspiration biopsy (IFNAB), and ipsilateral pleural recurrence (PR) after lung cancer surgery.
METHODS: Between 2008 and 2017, 1,047 patients with non-small cell lung cancer (NSCLC) underwent curative lung resection in our institution. They were divided into two groups: those in whom the first recurrent site was the ipsilateral pleural cavity (PR group) and the others (control group). Risk factors of PR were investigated retrospectively.
RESULTS: Recurrence was observed in 191 patients (18.2%), 25 of whom were categorized to the PR group (17 malignant effusion, 10 dissemination). Pathological tumor [2-4], lymph nodes [1-2], pleural, lymphatic and vascular invasion (each ≥1) factors and patients who underwent PCTGNB were more frequently observed in the PR group than in the control group (each P<0.01) whereas the proportion of patients who underwent IFNAB was not significant. A multivariate analysis identified pathological lymph node factor and the frequency of PCTGNB as independent risk factors for PR with hazard ratios of 7.33 (95% CI, 2.93-19.8; P<0.01) and 6.92 (95% CI, 2.25-17.8; P<0.01), respectively.
CONCLUSIONS: PCTGNB is a risk factor of PR but IFNAB is not. Indications for PCTGNB should be carefully determined. 2020 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Computed tomography-guided needle biopsy; intraoperative fine-needle aspiration biopsy (IFNAB); pleural recurrence (PR)

Year:  2020        PMID: 32642171      PMCID: PMC7330316          DOI: 10.21037/jtd.2020.03.16

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


Introduction

Preoperative computed tomography-guided needle biopsies (PCTGNBs) and intraoperative fine-needle aspiration biopsies (IFNABs) are valuable examinations for the evaluation of indeterminate pulmonary nodules with high accuracy and safety for the detection of malignancy (1-4), therefore they are important alternatives to trans-bronchial biopsies (TBBs) through bronchofiber scopes or surgical resection. However, several complications of PCTGNB and IFNAB have been reported, including tumor seeding and increasing the frequency of ipsilateral pleural recurrence (PR) (5-7). Although it is not conclusive whether such needle aspiration can be a potential hazard of PR, the two modalities are being applied in practice. On the other hand, PR with pleural dissemination or malignant effusion has sometimes been experienced in cases of pathologic stage IA lung cancer. We conducted a retrospective study to identify potential risk factors of PR in patients with non-small cell lung cancer (NSCLC) after curative resection, especially focusing on whether PCTGNB and IFNAB are related to PR.

Methods

Patients

We performed a retrospective chart review of the 1,333 primary lung cancer patients who underwent curative lung resection at Chiba University Hospital between 2008 and 2017. Among them, patients with non-synchronous multiple primaries (n=163), incomplete resections (n=71), small cell lung cancer components (n=39), Tis (n=11), or no pulmonary resections (n=2) were excluded. The remaining 1,047 patients were divided into two groups: those who were diagnosed with pleural dissemination or malignant effusion ipsilateral to the operated side as the first recurrent site (PR group, n=25), and the others (control group, n=1,022), including patients without any recurrences (n=856) and those with recurrences other than PR (n=166) ().
Figure 1

Study population.

Study population. All the patients’ medical histories, surgical records, and radiological as well as pathological results were reviewed. The pathological diagnosis was determined according to the World Health Organization lung cancer classification. The staging was determined according to the 7th lung cancer TNM classification and staging system. The Ethics Committee at Chiba University approved this study (No. 3045) and written consent was waived due to the study being a retrospective chart review.

PCTGNB procedure

In principal, PCTGNB is applied to patients that have no indication or cannot be diagnosed with TBB. Briefly, a 16-gauge co-axial system needle was guided into the lesion though the intercostal space under real-time computed tomography (CT) imaging with local anesthesia. Fine-needle aspiration cytology with a 21- or 22-gauge single needle was occasionally used in patients who had emphysematous lungs or centrally located lesions to avoid complications, such as critical pneumothorax or pulmonary hemorrhage.

IFNAB procedure

IFNAB was applied to patients who had a preoperatively undiagnosed peripheral mass in the outer one-third of the lung parenchyma. At the time of surgery, the tumor was detected by ocular inspection or by palpation. Aspiration cytology was performed using a 22-gauge single needle attached to a syringe through the pulmonary parenchyma. This process was generally repeated twice to obtain an adequate specimen. The specimen was carried to cytologists/pathologists, subjected to Giemsa stain, and the results were conveyed to the operation room within 20 to 30 minutes. When the specimens were not sufficient to diagnose, surgical biopsy by wedge resection was performed. IFNAB was usually applied with electrocoagulation for hemostasis.

Follow-up strategy

All patients had undergone a curative resection, including systematic nodal dissection (the area of which was defined according to the criteria of the Japan Lung Cancer Society), and were subjected to the routine follow-up protocol in our outpatient clinic. The physical examination included: clinical blood tests, including blood cell counts, hepatic enzymes, creatinine, total protein and tumor markers (carcinoembryonic antigen, cytokeratin 19 fragments and pro-gastrin-releasing peptide); and chest X-rays, which were performed every 3 months for the first 2 years and every 6 months thereafter until 5 years after surgery. A thoraco-abdominal CT scan was routinely taken every 6 months, while a bone scan and brain magnetic resonance imaging were performed every 12 months during the follow-up period. After 5 years, an annual CT scan was optionally taken. If there were any subjective or objective symptoms, further relevant examinations were promptly performed. When recurrence was suspected based on imaging, a biopsy was performed for the diagnosis of recurrence if possible.

Assessment of PR

PR was defined as the development of a pleural lesion or malignant effusion, or both, in the hemithorax of the operated side at the first relapse. Malignant pleural effusion was diagnosed cytologically, and pleural dissemination was diagnosed when multiple enhanced pleural lesions were observed on the chest CT. Positron emission tomographic-CT was used in several recent cases to support the diagnosis.

Statistical analysis

Data are presented as mean ± SD. Student’s t test was used for continuous variables, and Pearson’s chi-squared test was used for categorical variables. A logistic regression model was used to calculate the probability of clinicopathological variables. Cox regression analysis was performed to identify the risk factors associated with PR after surgery. Actuarial recurrence curves were calculated by the Kaplan-Meier method. Differences in recurrence rate were assessed by the log-rank test. All tests were two-sided and a P value of <0.05 was used to define statistical significance. Statistical analyses were performed using JMP (SAS, Cary, NC, USA).

Results

Of the 1,047 patients, recurrence occurred in 191 patients (18%), and 25 patients (2%) were in the PR group (pleural dissemination 8, pleural effusion 15, both dissemination and effusion 2). The follow-up periods in the two groups were comparable, with a median of 23.0 months in the PR group and 37.0 months in the control group. The clinicopathologic characteristics are summarized in . There was no significant difference in age, sex, the presence of chronic obstructive pulmonary disease or interstitial pneumonia, type of operative methods, histological types and the presence of micropapillary pattern between the two groups. Regarding the pathological findings of the tumor, tumor size was larger and lymph node metastasis was more common in the PR group than in the control group. In terms of diagnostic procedures, 5 of 25 patients (20%) in the PR group and 27 of 1,022 patients (3%) in the control group underwent PCTGNB, and there was a significant difference between the two groups (P<0.01). In contrast, the proportion of patients who underwent IFNAB was not significantly different between the two groups.
Table 1

Clinical and pathological characteristics of patients with pleural recurrence as the first recurrent site (n=1,047)

Clinical/pathological characteristicsPR group, n=25 [%]Control group, n=1,022 [%]P value
Age
   Mean70.7±7.767.8±9.10.18
   ≥70 years15 [60]482 [47]0.20
Male12 [48]656 [64]0.10
Right side11 [44]610 [60]0.11
Interstitial pneumonia3 [12]88 [9]0.55
COPD3 [12]202 [20]0.33
Operative method
   Partial resection1 [4]44 [4]0.74
   Segmentectomy5 [20]173 [17]Partial resection + segmentectomy vs. others
   Lobectomy19 [76]763 [75]
   Bilobectomy0 [0]30 [3]
   Pneumonectomy0 [0]12 [1]
Histology
   Ad19 [76]738 [72]0.68
   Sq4 [16]218 [21]Ad. vs. others
   Others2 [8]66 [6]
Pathological T factor
   T15 [20]579 [57]<0.01
   T218 [72]359 [35]T1 vs. others
   T32 [8]65 [6]
   T40 [0]19 [2]
Pathological N factor
   N08 [32]803 [79]<0.01
   N18 [32]91 [9]N0 vs. N1-3
   N28 [32]105 [10]
   N30 [0]1 [0]
   NX1 [4]22 [2]
Pathological Pl factor
   Pl011 [44]792 [78]<0.01
   Pl18 [32]124 [12]Pl0 vs. others
   Pl23 [12]41 [4]
   Pl33 [12]57 [6]
   Pl3 (interlobar)0 [0]8 [1]
Pathological lymph vascular invasion
   v0 and ly09 [36]641 [65]<0.01
   v1-2 or ly116 [64]352 [35]
Micropapillary pattern component
   ≥1%4 [16]78 [8]0.12
   ≥5%5 [20]106 [10]0.12
PCTGNB5 [20]27 [3]<0.01
IFNAB2 [8]163 [16]0.28

COPD, chronic obstructive pulmonary disease; Ad, adenocarcinoma; Sq, squamous cell carcinoma; PCTGNB, postoperative computed tomography guided needle biopsy; IFNAB, intraoperative fine needle aspiration biopsy; NA, not applicable.

COPD, chronic obstructive pulmonary disease; Ad, adenocarcinoma; Sq, squamous cell carcinoma; PCTGNB, postoperative computed tomography guided needle biopsy; IFNAB, intraoperative fine needle aspiration biopsy; NA, not applicable. To determine the risk factors for PR, univariate and multivariate Cox regression analyses were performed (). The univariate analysis identified pathological tumor (T), lymph nodes (N), pleural invasion (Pl), lymphatic invasion (ly) and vascular invasion (v) factors and PCTGNB as risk factors for PR (P<0.01). Among them, the hazard ratio (HR) of pathological N factor was the highest at 14.8 [95% confidence interval (CI), 7.52–29.1] of all factors. The HR of PCTGNB was 7.44 (95% CI, 2.47–18.4); however, IFNAB was not identified as a risk factor (HR, 0.43; 95% CI, 0.07–1.45). A multivariate analysis revealed pathological N factor and the frequency of PCTGNB as independent risk factors for PR, with HRs of 7.14 (95% CI, 2.84–19.4; P<0.01) and 7.16 (95% CI, 2.33–18.3; P<0.01), respectively.
Table 2

Univariate and multivariate analyses of risk factors of pleural recurrence

VariablesUnivariate analysisMultivariate analysis
Hazard ratio (95% CI)P valueHazard ratio (95% CI)P value
Age (≥70 years)1.79 (0.15–4.11)0.15NANA
Male0.55 (0.25–1.20)0.13NANA
Right side0.54 (0.29–1.18)0.12NANA
Interstitial pneumonia1.78 (0.42–5.14)0.38NANA
COPD0.54 (0.13–1.59)0.28NANA
Operative method (partial resection & segmentectomy)1.08 (0.39–2.55)0.74NANA
Adenocarcinoma1.09 (0.46–3.00)0.85NANA
≥ T210.0 (4.39–24.8)<0.012.60 (0.82–8.99)0.10
≥ N114.8 (7.52–29.1)<0.017.14 (2.84–19.4)<0.01
≥ Pl14.87 (2.21–11.0)<0.011.58 (0.62–4.35)0.34
Lymph vascular invasion3.61 (1.63–8.53)<0.011.05 (0.40–2.94)0.92
PCTGNB7.44 (2.47–18.4)<0.017.16 (2.33–18.3)<0.01
IFNAB0.43 (0.07–1.45)0.20NANA

CI, confidence interval; COPD, chronic obstructive pulmonary disease; PCTGNB, postoperative computed tomography guided needle biopsy; IFNAB, intraoperative fine needle aspiration biopsy; NA, not applicable.

CI, confidence interval; COPD, chronic obstructive pulmonary disease; PCTGNB, postoperative computed tomography guided needle biopsy; IFNAB, intraoperative fine needle aspiration biopsy; NA, not applicable. The 5-year PR rate of patients who underwent PCTGNB (n=32) was higher at 18.3% than that of the others at 2.6% (n=1,015, P<0.01 by the log-rank test, ). On the other hand, the 5-year PR rate of the IFNAB group (n=165) was 1.7% and that of the others (n=882) was 3.4%; there was no significant difference (P=0.20) ().
Figure 2

Pleural recurrence rates. (A) Kaplan-Meier analysis of the comparison of time to pleural recurrence between the PCTGNB and no PCTGNB groups. PCTGNB; preoperative computed tomographic guided needle biopsy; (B) Kaplan-Meier analysis of the comparison of time to pleural recurrence between the IFNAB and no IFNAB groups. IFNAB, intraoperative fine-needle aspiration biopsy.

Pleural recurrence rates. (A) Kaplan-Meier analysis of the comparison of time to pleural recurrence between the PCTGNB and no PCTGNB groups. PCTGNB; preoperative computed tomographic guided needle biopsy; (B) Kaplan-Meier analysis of the comparison of time to pleural recurrence between the IFNAB and no IFNAB groups. IFNAB, intraoperative fine-needle aspiration biopsy. The details of 5 patients with PR after surgery and who underwent PCTGNB are individually summarized in . Pathological N2 was observed in 2 patients and pathological Pl2 or 3 was observed in another 2 patients. However, a case of early-stage NSCLC was found. The tumor had a very low risk of recurrence because it was equivalent to a minimally invasive adenocarcinoma in the 8th lung cancer TNM classification. Therefore, it was strongly suspected that tumor seeding really occurred and was associated with PR in that case.
Table 3

Clinicopathologic characteristics of 5 patients with pleural recurrence after PCTGNB

Age/sexNeedle gaugeNumber of needle passesOperative methodHistologySize (cm)T/N/pl/v/lyRecurrence patternConcomitant recurrences
WholeSolid
54/FNA2Rt. S8 segmentectomyAd1.60.51a/0/0/0/0DisseminationNo
75/MNA1LingulectomySq2.82.81b/2/0/0/1EffusionNo
80/MNA2RULAd1.41.42a/0/2/0/0EffusionNo
73/M16G3RMLAd3.23.22a/2/0/1/1EffusionPUL
77/MNANALUL + CWRSq6.86.83c/0/3/1/0DisseminationPUL, OSS, LYM

RUL, right upper lobectomy; RML, right middle lobectomy; LUL, left upper lobectomy; CWR, chest wall resection; Ad, adenocarcinoma; Sq, squamous cell carcinoma; PUL, pulmonary; OSS, bone; LYM, lymph node; NA, not applicable.

RUL, right upper lobectomy; RML, right middle lobectomy; LUL, left upper lobectomy; CWR, chest wall resection; Ad, adenocarcinoma; Sq, squamous cell carcinoma; PUL, pulmonary; OSS, bone; LYM, lymph node; NA, not applicable.

Discussion

This study analyzed risk factors for PR, especially focusing on diagnostic needle biopsies such as PCTGNB and IFNAB in patients with lung cancer who underwent curative resection. When it comes to recurrence in the pleural cavity, even in early disease in surgical pathology, patients generally have a poor prognosis and are considered unsuitable candidates for local therapy (8). Moreover, treatment and the control of malignant pleural effusions sometimes become extremely difficult (9). Therefore, it is very important to identify risk factors of PR and to prevent tumor seeding by preoperative diagnosis or operative procedures. Although PCTGNB is widely used for histological diagnosis because of its high accuracy at 92.1% (1), several complications associated with this examination have been reported (5-7). According to a questionnaire survey, the most frequent complication is pneumothorax with a reported rate of approximately 20.5–35%, followed by hemoptysis (5.3%), hemothorax (0.09%), air embolism (0.06%) and tumor seeding (0.01–0.06%) (6,10,11). However, the true incidence of tumor seeding along the needle tract may be underestimated because not all cases are fully followed-up. Therefore, it is necessary to follow patients for several years to clinically identify dissemination after the procedure. Several reports have indicated that PCTGNB influences PR in completely resected lung cancer (12,13) but other studies have shown conflicting results (14-17). A recent meta-analysis concluded that PCTGNB does not increase the risk of PR; however, a subgroup analysis in that study showed that PCTGNB is associated with increased PR in cases with sub-pleural lesions (18). This is likely inconclusive because the meta-analysis was based on only 5 single-center retrospective studies with small samples. In addition, different characteristics, procedure criteria and puncture methods could be also confounding factors and might affect the outcome. Another study using the inverse probability-weighted model to adjust for characteristics demonstrated that PCTGNB was an independent risk factor of PR (19). We conducted a multivariate analysis to minimize the influences of confounding factors like patients’ characteristics and pathological factors and found that PCTGNB was an independent risk factor of PR after lung resection. Therefore, we propose that PCTGNB should be limited to cases that absolutely require a pathological diagnosis for deciding treatment strategy. IFNAB can minimize the time until radical surgery for peripheral lung cancer by avoiding further examinations and is the simplest and most direct method for diagnosing lung tumors (3). This examination is considered to increase the potential risk of PR through needle tracts like PCTGNB, though there is no clear evidence in this study. An experimental study demonstrated a significantly higher pleural dissemination potential by performing pleural washing and cytology on resected lungs before and after IFNAB. Cytology positive for malignancy was found in 60% of the post-IFNAB specimens compared with 10% of the pre-IFNAB specimens (20). However, a single-center retrospective study indicated that IFNAB did not increase the risk of pleural dissemination (3). In our study, there were only 2 patients (8% of IFNAB) who experienced PR after surgery with IFNAB and there was no relationship between IFNAB and PR. The 2 patients had other risk factors for PR such as N1 and N2. It is also evident that seeded cancer cells cannot always generate pleural dissemination, as it probably requires several other factors, such as adhesion, vascular generation, and transformation (3). Disseminated cancer cells at the time of IFNAB might be washed out by irrigation with warm saline just before closure of the thorax. Lymph node metastasis is known to be one of the most powerful factors leading to a poor prognosis in patients with completely resected cancer due to high local and distant recurrence rates (21,22). Our results indicate that the existence of metastatic lymph nodes clearly influences PR. Possible mechanisms to explain this are that the cancer cells metastasizing to the lymph nodes were exposed to the pleural cavity or were blocking lymphatic drainage from the lung parenchyma, or that the metastatic nodes were destroyed during surgery, leading to the direct seeding of cancer cells. Although further investigation is required to prove these mechanisms, it is important information to surgeons. Relevant limitations of this monocentric study are the retrospective design of the data and the relatively small number of patients. Patients who were diagnosed with pleural disease at the time of thoracotomy were omitted from this study because it is difficult to distinguish natural pleural disease and artificial pleural dissemination. During the study period, malignant pleurisy and intrathoracic dissemination were first found during surgery in 21 patients, 2 of which had undergone PCTGNB. Another limitation may be a potential selection bias. PCTGNB might have been applied to peripherally located tumors. Further investigation would be required to provide robust evidence on the potential impact of these practical issues. In conclusion, although IFNAB was not a risk factor of postoperative PR, the PCTGNB procedure is strongly associated with the occurrence of PR after curative resection in this study. As there is not only the risk of tumor seeding, but also the risk of the other complications like pneumothorax, indications for PCTGNB should be carefully considered for the candidates of NCSLC resection. Alternatively, IFNAB or intraoperative rapid diagnosis of frozen sections acquired from a minimal surgical resection is more recommended for patients whose pulmonary lesion is suspicious of lung cancer but not diagnosed cytologically or pathologically. The article’s supplementary files as
  22 in total

1.  Percutaneous lung biopsies: a survey of UK practice based on 5444 biopsies.

Authors:  C M Richardson; K S Pointon; A R Manhire; J T Macfarlane
Journal:  Br J Radiol       Date:  2002-09       Impact factor: 3.039

2.  Risk of pleural recurrence after percutaneous transthoracic needle biopsy in stage I non-small-cell lung cancer.

Authors:  Su Yeon Ahn; Soon Ho Yoon; Bo Ram Yang; Young Tae Kim; Chang Min Park; Jin Mo Goo
Journal:  Eur Radiol       Date:  2018-06-15       Impact factor: 5.315

3.  Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.

Authors:  Mitsuhiro Isaka; Hideaki Kojima; Shoji Takahashi; Katsuhiro Omae; Yasuhisa Ohde
Journal:  Lung Cancer       Date:  2017-11-16       Impact factor: 5.705

4.  Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.

Authors:  Seong Mi Moon; Dae Geun Lee; Na Young Hwang; Soohyun Ahn; Hyun Lee; Byeong-Ho Jeong; Yong Soo Choi; Young Mog Shim; Tae Jeong Kim; Kyung Soo Lee; Hojoong Kim; O Jung Kwon; Kyung Jong Lee
Journal:  Lung Cancer       Date:  2017-07-12       Impact factor: 5.705

5.  Preoperative Percutaneous Transthoracic Needle Biopsy Increased the Risk of Pleural Recurrence in Pathological Stage I Lung Cancer Patients With Sub-pleural Pure Solid Nodules.

Authors:  Kosuke Kashiwabara; Hiroshi Semba; Shinji Fujii; Shinsuke Tsumura
Journal:  Cancer Invest       Date:  2016-08-17       Impact factor: 2.176

Review 6.  Needle-track metastasis after transthoracic needle biopsy.

Authors:  D Ayar; B Golla; J Y Lee; H Nath
Journal:  J Thorac Imaging       Date:  1998-01       Impact factor: 3.000

Review 7.  Percutaneous needle biopsy of the lung and its impact on patient management.

Authors:  J M Murphy; F V Gleeson; C D Flower
Journal:  World J Surg       Date:  2001-04-11       Impact factor: 3.352

8.  CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan.

Authors:  Noriyuki Tomiyama; Yoshifumi Yasuhara; Yasuo Nakajima; Shuji Adachi; Yasuaki Arai; Masahiko Kusumoto; Kenji Eguchi; Keiko Kuriyama; Fumikazu Sakai; Masayuki Noguchi; Kiyoshi Murata; Sadayuki Murayama; Teruhito Mochizuki; Kiyoshi Mori; Kozo Yamada
Journal:  Eur J Radiol       Date:  2006-03-10       Impact factor: 3.528

9.  Intraoperative fine needle aspirations - diagnosis and typing of lung cancer in small biopsies: challenges and limitations.

Authors:  Christian Biancosino; Marcus Krüger; Ekkehard Vollmer; Lutz Welker
Journal:  Diagn Pathol       Date:  2016-07-07       Impact factor: 2.644

Review 10.  Management of malignant pleural effusion: challenges and solutions.

Authors:  Erika Penz; Kristina N Watt; Christopher A Hergott; Najib M Rahman; Ioannis Psallidas
Journal:  Cancer Manag Res       Date:  2017-06-23       Impact factor: 3.989

View more
  1 in total

1.  Effect of intraoperative needle biopsy on the survival of nonsmall cell lung cancer patients: a propensity score matching analysis.

Authors:  Mizuki Morota; Masaaki Nagano; Naohiro Ijiri; Nobuyuki Yoshiyasu; Yoshikazu Shinohara; Yuya Nobori; Hirokazu Yamaguchi; Shun Kawashima; Masahiro Yanagiya; Chihiro Konoeda; Kentaro Kitano; Masaaki Sato; Jun Nakajima
Journal:  Surg Today       Date:  2022-03-03       Impact factor: 2.540

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.